share_log

Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany

Benzinga ·  May 8 07:23
Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment